GLYCAM1: A Potential Drug Target and Biomarker (G644076)

Target Name: GLYCAM1

NCBI ID: G644076

GLYCAM1

Other Name(s): Glycosylation dependent cell adhesion molecule 1 (pseudogene) | glycosylation dependent cell adhesion molecule 1 (pseudogene)

GLYCAM1: A Potential Drug Target and Biomarker

Glycosylation-dependent cell adhesion molecule 1 (GlyCAM1) is a protein that plays a critical role in cell-cell adhesion and has been identified as a potential drug target and biomarker. GlyCAM1 is a cytoplasmic protein that is expressed in most tissues and cells, including neural, epithelial, and hematopoietic cells. It is a member of the integrin receptor family, which includes proteins that are involved in cell-cell adhesion, migration, and invasion.

GlyCAM1 was first identified in the 1990s as a cell adhesion molecule that is targeted by integrins, which are proteins that are involved in cell-cell adhesion. Integrins are transmembrane proteins that are composed of an extracellular domain that is involved in cell-cell adhesion, as well as an intracellular domain that is involved in signal transduction and intracellular signaling. GlyCAM1 is specifically targeted by the integrin 伪6 (伪6) chain, which is a member of the 伪6 Integrin subfamily.

GlyCAM1 is involved in cell-cell adhesion by playing a role in the formation of tight junctions, which are specialized junctions that form when two cells become connected. Tight junctions are specialized barriers that prevent cells from coming into direct contact with each other and are involved in maintaining tissue structure and function. GlyCAM1 is involved in the formation of tight junctions by helping to regulate the activity of the cadherins, which are a family of transmembrane proteins that are involved in cell-cell adhesion.

In addition to its role in cell-cell adhesion, GlyCAM1 is also involved in the regulation of cell proliferation and survival. GlyCAM1 has been shown to play a role in the regulation of cell cycle progression, as well as the regulation of cell survival and apoptosis. . GlyCAM1 has also been shown to play a role in the regulation of angiogenesis, as well as the regulation of tissue repair and regeneration.

GlyCAM1 has also been identified as a potential drug target and biomarker. GlyCAM1 has been shown to be involved in a variety of signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. GlyCAM1 has also have been shown to play a role in the regulation of cell adhesion and the formation of tight junctions, as well as the regulation of cell proliferation and survival. These properties make GlyCAM1 a potential drug target and biomarker for a variety of diseases.

One of the challenges in targeting GlyCAM1 as a drug or biomarker is its complex structure. GlyCAM1 is a cytoplasmic protein that is expressed in most tissues and cells, making it difficult to target specifically. In addition, GlyCAM1 is involved in the regulation of a variety of cellular processes, making it difficult to identify and target specific interactions with drugs or other therapeutic agents.

In conclusion, GlyCAM1 is a protein that plays a critical role in cell-cell adhesion and has been identified as a potential drug target and biomarker. Its structure and function make it difficult to target specifically, but its involvement in a variety of cellular processes makes it a promising target for future therapeutic interventions. Further research is needed to fully understand the role of GlyCAM1 in cell-cell adhesion and its potential as a drug or biomarker.

Protein Name: Glycosylation Dependent Cell Adhesion Molecule 1 (pseudogene)

The "GLYCAM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLYCAM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets